BPC-157 oral vs injectable
BPC-157 is sold in both oral capsule and injectable lyophilized forms. The two routes have very different pharmacokinetics: injectable produces systemic plasma levels and reaches distant tissues; oral mostly stays in the GI tract with limited systemic effect. Both have plausible use cases; they aren't interchangeable.
Why oral peptides struggle
BPC-157 is a 15-amino-acid peptide. Like any peptide, it faces the three GI barriers:
- Stomach acid (pH ~1.5) denatures peptide structure.
- Gut proteases (pepsin, trypsin, chymotrypsin) chop peptides into amino acids.
- Epithelial barrier in stomach and intestine doesn't pass molecules above ~500 Da efficiently. BPC-157 is ~1,419 Da — over the threshold.
Without an absorption enhancer (like SNAC in oral semaglutide — see SNAC explained), most of an orally administered peptide is degraded in the gut before systemic absorption.
BPC-157's particular case
BPC-157's parent sequence (Body Protective Compound) is naturally occurring in gastric mucosa — it's a fragment of a larger protein produced in the human stomach. This origin gives it an unusual property: BPC-157 appears to be more resistant to gastric degradation than most peptides, possibly because it evolved in that environment.
Some studies in rodents have shown measurable oral bioavailability (perhaps 5–10% of injected dose reaches systemic circulation). This is much better than typical peptides but still poor compared to injection.
What oral BPC-157 can do
Local effects in the GI tract:
- Gastric mucosal healing. The original BPC research focused on ulcer healing — oral delivery puts the peptide directly where it's needed.
- Inflammatory bowel-related applications. Some preclinical data suggests local effects on colonic inflammation.
- Esophageal reflux mucosal protection. Limited evidence but mechanistically plausible.
Note: these are all local effects, achievable because the peptide is in direct contact with the target tissue. No systemic absorption is required.
What oral BPC-157 cannot reliably do
- Distant musculoskeletal healing. Tendon, ligament, joint repair — the historical use case for BPC-157 — requires systemic delivery to reach those tissues. Oral bioavailability is too low.
- Neurological effects. Reaching brain tissue requires plasma exposure; oral doesn't deliver enough.
- Vascular effects. Distant capillary effects need systemic plasma.
Comparing the routes
| Property | Oral BPC-157 | Injectable BPC-157 |
|---|---|---|
| Systemic bioavailability | ~5–10% of dose | ~95–100% of dose |
| Time to peak plasma | ~2–4 hours | ~30–60 minutes |
| Best for | GI mucosal targets | Musculoskeletal, neuro, vascular targets |
| Convenience | Capsules; no needles | Subq injection daily/several times weekly |
| Typical dose | 200–500 mcg orally | 250–500 mcg subq |
| Cost per equivalent systemic exposure | ~10× higher (need 10× dose) | ~1× baseline |
| Tachyphylaxis pattern | Less, due to lower systemic exposure | Reported in some long-term users |
Sublingual: a middle ground
Some BPC-157 products are marketed as "sublingual" — held under the tongue for absorption through the oral mucosa, bypassing the GI tract. Theoretically this avoids gastric degradation; practically, the absorption rate of a 1,419 Da peptide through oral mucosa is poor. Sublingual BPC-157 likely sits between oral (5–10% bioavailability) and injectable (95–100%), perhaps 15–25% bioavailability.
Sublingual is a reasonable compromise for users who can't inject but want better-than-oral systemic effect. It's not equivalent to injection.
Practical implications
- If the goal is GI healing (gastritis, ulcers, IBS-related issues), oral BPC-157 makes sense. Direct delivery to the target.
- If the goal is systemic healing (tendon, joint, ligament, soft tissue), injection is the only route with adequate exposure. Oral at "equivalent dose" mostly doesn't reach the target tissue.
- Don't compare oral and injectable doses at face value. 500 mcg oral and 500 mcg injectable are not the same systemic exposure.
- If switching from oral to injectable, dose-equivalent injectable is roughly 1/10 of the oral dose for the same systemic effect. A 500 mcg injectable dose ≈ 5,000 mcg oral.
FAQ
Why do online dose recommendations often use the same numbers for oral and injectable?
They shouldn't. Many community-circulated dosing protocols ignore the bioavailability gap. Following injectable-dose recommendations for oral capsules will dramatically underdose the systemic effect.
Are oral BPC-157 capsules just dried injectable?
Sometimes. Many oral products are simply lyophilized peptide in a capsule shell, identical to what would be reconstituted for injection. The difference is the route of administration, not the molecule.
Does food affect oral BPC-157 absorption?
Limited data. Empty stomach is the default recommendation, similar to oral semaglutide, on the assumption that food disrupts whatever absorption pathway exists. Take 30+ minutes before food.
Is oral safer than injectable?
Less systemic exposure means less systemic risk of unknown effects. Local GI effects (irritation, micro-thrombosis at gastric capillaries) are the trade-off. Both routes are unapproved for human use and carry the broader regulatory and quality concerns covered in <a href="/blog/bpc-157-tb-500-fda-warnings-immunogenicity/">FDA warnings on BPC-157 and TB-500</a>.
Related reading
Compare routes correctly
Peptide Protocol distinguishes oral and injectable protocols and shows the actual systemic exposure for each.
Get the iPhone app →Informational and educational only. Not medical advice. Consult a licensed clinician before starting, changing, or stopping any peptide protocol. Mentions of investigational, compounded, or research-use peptides are for informational purposes; many such substances are not FDA-approved for human use.